On December 10, 2025, Apimeds Pharmaceuticals US, Inc. (APUS) disclosed multiple corporate actions in an SEC 8-K filing. The filing reported the company entered into a merger agreement and secured $120.9 million in financing through an amended securities purchase agreement.

According to the filing, Apimeds Pharmaceuticals US, Inc. executed an Agreement and Plan of Merger on December 1, 2025, with MindWave Innovations Inc, Lokahi Therapeutics, Inc., and Erik Emerson. The merger involves Apimeds Merger Sub, Inc. as a subsidiary, according to Exhibit 2.1 attached to the filing.

The company also amended a securities purchase agreement on December 8, 2025, with an institutional investor, securing an aggregate principal amount of $120.9 million in senior convertible notes. President Erik Emerson signed the agreement on behalf of Apimeds Pharmaceuticals US, Inc., according to the document.

In a separate regulatory action, the company filed a corrected Certificate of Designation for its Series A Convertible Preferred Stock with the Delaware Secretary of State on December 10, 2025. CEO Vin Menon signed the Certificate of Correction, which was filed as Exhibit 3.1.